Abstract
Rheumatoid arthritis (RA) is the most commonly occurring, progressive, autoimmune disease, affecting 1% of the population and the ratio of affected women is three times as compared to men in most developing countries. Clinical manifestations of RA are the presence of anti-citrullinated protein antibody (ACPA) and rheumatoid factor (RF) in blood, tendered joints and soreness of the muscles. Some other factors which may lead to chronic inflammation are genetic and environmental factors as well as adaptive immune response. Several conventional drugs are available for the treatment of RA but have their own drawbacks which can be overcome by the use of novel drug delivery systems. The objective of the present review is to focus on the molecular pathogenesis of the disease and its current conventional treatment with special reference to the role of novel drug delivery systems encapsulating anti-rheumatic drugs and herbal drugs in passive and receptor-mediated active targeting against RA. On reviewing the conventional and current therapeutics against RA, we conclude that although the current therapy for the treatment of RA is capable enough, yet more advances in the field of targeted drug delivery will sanguinely result in effective and appropriate treatment of this autoimmune disease.
Keywords: Rheumatoid arthritis, autoimmune disease, conventional drugs, novel drug delivery systems, lipogelosomes, nanosponges, liposomes, herbal drugs.
Current Pharmaceutical Design
Title:Novel Nano Carriers for the Treatment of Progressive Auto Immune Disease Rheumatoid Arthritis
Volume: 27 Issue: 21
Author(s): Ritu Mishra and Swati Gupta*
Affiliation:
- Department of Pharmaceutics, Amity Institute of Pharmacy, Amity University Uttar Pradesh Sector-125, Noida-201303, U.P.,India
Keywords: Rheumatoid arthritis, autoimmune disease, conventional drugs, novel drug delivery systems, lipogelosomes, nanosponges, liposomes, herbal drugs.
Abstract: Rheumatoid arthritis (RA) is the most commonly occurring, progressive, autoimmune disease, affecting 1% of the population and the ratio of affected women is three times as compared to men in most developing countries. Clinical manifestations of RA are the presence of anti-citrullinated protein antibody (ACPA) and rheumatoid factor (RF) in blood, tendered joints and soreness of the muscles. Some other factors which may lead to chronic inflammation are genetic and environmental factors as well as adaptive immune response. Several conventional drugs are available for the treatment of RA but have their own drawbacks which can be overcome by the use of novel drug delivery systems. The objective of the present review is to focus on the molecular pathogenesis of the disease and its current conventional treatment with special reference to the role of novel drug delivery systems encapsulating anti-rheumatic drugs and herbal drugs in passive and receptor-mediated active targeting against RA. On reviewing the conventional and current therapeutics against RA, we conclude that although the current therapy for the treatment of RA is capable enough, yet more advances in the field of targeted drug delivery will sanguinely result in effective and appropriate treatment of this autoimmune disease.
Export Options
About this article
Cite this article as:
Mishra Ritu and Gupta Swati*, Novel Nano Carriers for the Treatment of Progressive Auto Immune Disease Rheumatoid Arthritis, Current Pharmaceutical Design 2021; 27 (21) . https://dx.doi.org/10.2174/1381612826666201021130146
DOI https://dx.doi.org/10.2174/1381612826666201021130146 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antiangiogenic Therapy
Current Pharmaceutical Design The Value of Elastosonography in Evaluation of Thyroid Nodules
Recent Patents on Medical Imaging Exploiting Cyclooxygenase-(in)Dependent Properties of COX-2 Inhibitors for Malignant Glioma Therapy
Anti-Cancer Agents in Medicinal Chemistry Resveratrol as a Chemopreventive Agent: A Promising Molecule for Fighting Cancer
Current Drug Targets Identification and Characterization of the Binding Sites of P-Glycoprotein for Multidrug Resistance-Related Drugs and Modulators
Current Medicinal Chemistry - Anti-Cancer Agents HPV-Specific Immunotherapy: Key Role for Immunomodulators
Anti-Cancer Agents in Medicinal Chemistry A Concise Review on Multidimensional Silver Nanoparticle Health Aids and Threats
Current Drug Therapy <i>In Vitro</i> Anticancer Effects of Stilbene Derivatives: Mechanistic Studies on HeLa and MCF-7 Cells
Anti-Cancer Agents in Medicinal Chemistry Targeting miRNAs for Pancreatic Cancer Therapy
Current Pharmaceutical Design Radiolabelling of Ascorbic Acid: A New Clue to Clarify its Action as an Anticancer Agent?
Current Radiopharmaceuticals Calcium Carbonate Microparticles as Carriers of <sup>224</sup>Ra: Impact of Specific Activity in Mice with Intraperitoneal Ovarian Cancer
Current Radiopharmaceuticals Applications of Aptamers in Targeted Imaging: State of the Art
Current Topics in Medicinal Chemistry Chemopreventive and Chemotherapeutic Potential of Curcumin in Breast Cancer
Current Drug Targets Tobacco, Inflammation, and Respiratory Tract Cancer
Current Pharmaceutical Design Inflammation, Microenvironment, and the Immune System in Cancer Progression
Current Pharmaceutical Design The Need for Calcium Channels in Cell Proliferation
Recent Patents on Anti-Cancer Drug Discovery The Use of PET for Radiotherapy
Current Medical Imaging Sera/Organ Lysates of Selected Animals Living in Polluted Environments Exhibit Cytotoxicity against Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Pharmacophore Modeling and 3D QSAR Studies of Novel Human Carbonic Anhydrase IX Inhibitors
Letters in Drug Design & Discovery Targeting the AKT Pathway in Glioblastoma
Current Pharmaceutical Design